Comparing Histogenics Corporation (HSGX) and Galena Biopharma (GALE)

Galena Biopharma (NASDAQ: GALE) and Histogenics Corporation (NASDAQ:HSGX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Galena Biopharma and Histogenics Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galena Biopharma 0 2 0 0 2.00
Histogenics Corporation 0 1 3 0 2.75

Galena Biopharma presently has a consensus price target of $2.78, indicating a potential upside of 718.37%. Histogenics Corporation has a consensus price target of $6.33, indicating a potential upside of 251.85%. Given Galena Biopharma’s higher probable upside, research analysts plainly believe Galena Biopharma is more favorable than Histogenics Corporation.

Valuation & Earnings

This table compares Galena Biopharma and Histogenics Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Galena Biopharma N/A N/A -$27.83 million ($1.76) -0.19
Histogenics Corporation N/A N/A -$25.96 million ($1.85) -0.97

Histogenics Corporation is trading at a lower price-to-earnings ratio than Galena Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Galena Biopharma and Histogenics Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galena Biopharma N/A -76.75% -28.16%
Histogenics Corporation N/A -440.61% -86.43%

Institutional and Insider Ownership

21.7% of Galena Biopharma shares are owned by institutional investors. Comparatively, 50.1% of Histogenics Corporation shares are owned by institutional investors. 0.8% of Galena Biopharma shares are owned by company insiders. Comparatively, 23.8% of Histogenics Corporation shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Galena Biopharma has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Histogenics Corporation has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Galena Biopharma Company Profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.

Histogenics Corporation Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

What are top analysts saying about Galena Biopharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galena Biopharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit